Roger C. Lipitz Center News and Updates
Our annual reports offer an in-depth look at the Center’s work, accomplishments of our students and faculty, and our publications for the year.
Read the Newsletter
The quarterly newsletter is the best way to learn about the Center’s latest research and policy initiatives, collaborations, and publications
Bloomberg School Stories
Spending on Consumer Advertising for Top-Selling Prescription Drugs in U.S. Favors Those With Low Added Benefit
Analysis found that more than two-thirds of top-selling prescription drugs in U.S.—one of two countries that allows direct marketing to consumers—were rated as having low added benefit compared to other drugs in 2020.
Insulin manufacturer Eli Lilly follows the government’s lead with a $35 price cap. Will manufacturers follow suit?